Role of inflammation in alcoholic liver diseases and its management
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253648Keywords:
Alcoholic liver disease, Inflammation, Tumor necrosis factor-alpha, Corticosteroids, S-adenosylmethionine, N-acetylcysteineAbstract
Alcoholic liver disease (ALD) weighs a heavy health burden in India with 76% increase in disability-adjusted life years (DALYs) through 1990 to 2016. This review examines the role of inflammation in its pathogenesis and management approaches for the same. The pathophysiology of ALD involves various mechanisms such as increased gut permeability, oxidative stress and activation of inflammatory cascade, where tumor necrosis factor-alpha (TNF-α) plays a central role. Due to these varied mechanisms, the clinical presentation also varies, ranging from asymptomatic fatty liver to severe cirrhosis. As such, the management strategies range from alcohol abstinence and nutritional support to pharmacological interventions. For inflammation-predominant ALD phenotypes such as alcoholic hepatitis, corticosteroids are often used as the primary therapy. Other agents, including S-adenosylmethionine (SAMe), pentoxifylline and N-acetylcysteine, show promise in targeting the inflammatory pathogenesis of ALD. SAMe is a more specific option for targeting inflammation, while N-acetylcysteine is best used where its potent anti-oxidant activity is desired. Ultimately, liver transplantation offers the terminal option for end-stage disease, with considerations for inflammation to subside before it can be done. This review highlights the complex inflammatory mechanisms underlying the ALD spectrum and discusses various multimodal approaches for incorporating various treatment strategies.
Metrics
References
Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194. DOI: https://doi.org/10.1038/ajg.2017.469
Patel R, Mueller M. Alcoholic Liver Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.google.com/search?q=https://www.nlm.nih.gov/books/NBK546632/%3Flog$vity. Accessed on 02 February 2024.
Gustot T, Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. J Hepatol. 2019;70(2):319-327. DOI: https://doi.org/10.1016/j.jhep.2018.12.008
Edmondson HA. Pathology of alcoholism. Am J Clin Pathol. 1980;74(5):725-42. DOI: https://doi.org/10.1093/ajcp/74.5.725
Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, et al. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep. 2021;8:376-385. DOI: https://doi.org/10.1016/j.toxrep.2021.02.010
Hernández-Évole H, Jiménez-Esquivel N, Pose E, Bataller R. Alcohol-associated liver disease: Epidemiology and management. Ann Hepatol. 2024;29(1):101162. DOI: https://doi.org/10.1016/j.aohep.2023.101162
Ray G, Manjubhargav P. Clinical Presentation and Mortality Determinants of Alcohol-Related Liver Disease: A Single-Center Experience of the Rising Menace from Eastern India. Inflamm Intest Dis. 2019;4(3):104-14. DOI: https://doi.org/10.1159/000501274
Singh SP, Padhi PK, Narayan J, Singh A, Pati GK, Nath P, et al. Socioeconomic impact of alcohol in patients with alcoholic liver disease in eastern India. Indian J Gastroenterol. 2016;35(6):419-424. DOI: https://doi.org/10.1007/s12664-016-0699-z
Ray G. Trends of chronic liver disease in a tertiary care referral hospital in eastern India. Indian J Public Health. 2014;58(3):186–194. DOI: https://doi.org/10.4103/0019-557X.138630
Nand N, Malhotra P, Dhoot DK. Clinical Profile of Alcoholic Liver Disease in a Tertiary Care Centre and its Correlation with Type, Amount and Duration of Alcohol Consumption. J Assoc Physicians India. 2015;63:14-20.
Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. DOI: https://doi.org/10.21037/tgh.2019.09.08
Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22(48):10512-10522. DOI: https://doi.org/10.3748/wjg.v22.i48.10512
Stärkel P, Leclercq S, de Timary P, Schnabl B. Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. Clin Sci (Lond). 2018;132(2):199-212. DOI: https://doi.org/10.1042/CS20171055
Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol. 2014;20(9):2168-75. DOI: https://doi.org/10.3748/wjg.v20.i9.2168
Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999;94(1):200-7. DOI: https://doi.org/10.1111/j.1572-0241.1999.00797.x
Rao RK, Seth A, Sheth P. Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G881-4. DOI: https://doi.org/10.1152/ajpgi.00006.2004
Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. DOI: https://doi.org/10.1155/2012/853175
Yang YM, Cho YE, Hwang S. Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease. Int J Mol Sci. 2022;23(2):774. DOI: https://doi.org/10.3390/ijms23020774
Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, et al. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm. 2013;2013:495156. DOI: https://doi.org/10.1155/2013/495156
Nath P, Anand AC. Extrahepatic Manifestations in Alcoholic Liver Disease. J Clin Exp Hepatol. 2022;12(5):1371-1383. DOI: https://doi.org/10.1016/j.jceh.2022.02.004
Kovalic AJ, Cholankeril G, Satapathy SK. Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Transl Gastroenterol Hepatol. 2019;4:65. DOI: https://doi.org/10.21037/tgh.2019.08.09
Milić S, Lulić D, Štimac D, Ružić A, Zaputović L. Cardiac manifestations in alcoholic liver disease. Postgrad Med J. 2016;92(1086):235-9. DOI: https://doi.org/10.1136/postgradmedj-2015-133755
Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016;22(16):4079-90. DOI: https://doi.org/10.3748/wjg.v22.i16.4079
Choudhury BN, Jain A, Baruah U. Dermatological manifestations of chronic liver disease. Int J Res Dermatol. 2018;4(2):224-9. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20181824
Hernandez-Tejero M, Clemente-Sanchez A, Bataller R. Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease. J Clin Exp Hepatol. 2023;13(1):75-87. DOI: https://doi.org/10.1016/j.jceh.2022.10.002
Arteel GE, Crabb DW. Pathogenesis of Alcoholic Liver Disease. 41-69. DOI: https://doi.org/10.1007/978-3-319-20538-0_3
Abu-Abaa M, Kananeh S, Mousa A, Jumaah O. Direct/Conjugated Hyperbilirubinemia as an Uncommon Presentation of Acute Alcoholic Hepatitis: A Case Report. Cureus. 2023;15(4):e37548. DOI: https://doi.org/10.7759/cureus.37548
Vatsalya V, Royer AJ, Jha SK, Parthasarathy R, Tiwari H, Feng W, et al. Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease. Adv Clin Chem. 2023;114:83-108. DOI: https://doi.org/10.1016/bs.acc.2023.02.001
Mishra R, Garg S, Gowda RV, Bharti P, Sharma P. Atypical Presentation of Alcoholic Liver Disease as Isolated Direct Hyperbilirubinaemia with Non Resolving Pneumonia Secondary to Multidrug Resistant Escherichia coli and Aspergillus Co-infection: A Case Report. J Clin of Diagn Res. 2023;17(5):OD01-OD04. DOI: https://doi.org/10.7860/JCDR/2023/60417.17925
Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, et al. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut. 2022;71(9):1856-66. DOI: https://doi.org/10.1136/gutjnl-2021-324295
Sharma P, Arora A. Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis. Transl Gastroenterol Hepatol. 2020;5:19. DOI: https://doi.org/10.21037/tgh.2019.10.02
Dillon JF, Miller MH. Gamma glutamyl transferase 'To be or not to be' a liver function test? Ann Clin Biochem. 2016;53(6):629-31. DOI: https://doi.org/10.1177/0004563216659887
Kim E, Park SH. Diagnosis and Severity Assessment of Alcohol-Related Liver Disease. Korean J Gastroenterol. 2020;76(2):60-4. DOI: https://doi.org/10.4166/kjg.2020.76.2.60
Goel N, Agarwal BB, Sharma K. Alcoholic liver diseases: general diagnostic approach. International Journal of Contemporary Medical Research. 2019;6(9):I1-I6. DOI: https://doi.org/10.21276/ijcmr.2019.6.9.30
Whitfield JB, Zhu G, Madden PAF, Montgomery GW, Heath AC, Martin NG. Biomarker and Genomic Risk Factors for Liver Function Test Abnormality in Hazardous Drinkers. Alcohol Clin Exp Res. 2019;43(3):473-82. DOI: https://doi.org/10.1111/acer.13949
Ayares G, Idalsoaga F, Díaz LA, Arnold J, Arab JP. Current Medical Treatment for Alcohol-Associated Liver Disease. J Clin Exp Hepatol. 2022;12(5):1333-48. DOI: https://doi.org/10.1016/j.jceh.2022.02.001
Adekunle AD, Adejumo A, Singal AK. Therapeutic targets in alcohol-associated liver disease: progress and challenges. Therap Adv Gastroenterol. 2023;16:17562848231170946. DOI: https://doi.org/10.1177/17562848231170946
Xu MJ, Zhou Z, Parker R, Gao B. Targeting inflammation for the treatment of alcoholic liver disease. Pharmacol Ther. 2017;180:77-89. DOI: https://doi.org/10.1016/j.pharmthera.2017.06.007
Woo GA, O'Brien C. Long-term management of alcoholic liver disease. Clin Liver Dis. 2012;16(4):763-81. DOI: https://doi.org/10.1016/j.cld.2012.08.007
Marsano LS, Mendez C, Hill D, Barve S, McClain CJ. Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2003;27:247-56.
European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399-420. DOI: https://doi.org/10.1016/j.jhep.2012.04.004
Maher JJ. Alcoholic steatohepatitis: Management and prognosis. Curr Gastroenterol Rep. 2007;9:39-46. DOI: https://doi.org/10.1007/s11894-008-0019-6
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology. 2020;71:306-33. DOI: https://doi.org/10.1002/hep.30866
Vatsalya V, Li F, Frimodig J, Shah N, Sutrawe A, Feng W. Efficacy of Thiamine and Medical Management in Treating Hyperuricemia in AUD Patients with ALD: Role of Hyperuricemia in Liver Injury, Gut-Barrier Dysfunction, and Inflammation. Clin Exp Pharmacol. 2021;11(7):001.
Listabarth S, Vyssoki B, Marculescu R, Gleiss A, Groemer M, Trojer A, et al. Can thiamine substitution restore cognitive function in alcohol use disorder? Alcohol Alcohol. 2023;58(3):315-23. DOI: https://doi.org/10.1093/alcalc/agad017
Kalapatapu N, Skinner SG, D’Addezio EG, Ponna S, Cadenas E, Davies DL. Thiamine Deficiency and Neuroinflammation Are Important Contributors to Alcohol Use Disorder. Pathophysiology. 2025;32(3):34. DOI: https://doi.org/10.3390/pathophysiology32030034
Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context. 2015;4:212287. DOI: https://doi.org/10.7573/dic.212287
Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996;16(1):49-57. DOI: https://doi.org/10.1002/j.1875-9114.1996.tb02915.x
Nutt D, Adinoff B, Linnoila M. Benzodiazepines in the treatment of alcoholism. Recent Dev Alcohol. 1989;7:283-313. DOI: https://doi.org/10.1007/978-1-4899-1678-5_15
Song DS. Medical Treatment of Alcoholic Liver Disease. Korean J Gastroenterol. 2020;76(2):65-70. DOI: https://doi.org/10.4166/kjg.2020.76.2.65
Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781-1789. DOI: https://doi.org/10.1056/NEJMoa1101214
Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015;149:958-970.e12. DOI: https://doi.org/10.1053/j.gastro.2015.06.006
Purohit V, Russo D. Role of S-adenosyl-L-methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol. 2002;27(3):151-4. DOI: https://doi.org/10.1016/S0741-8329(02)00232-X
King AL, Mantena SK, Andringa KK, Millender-Swain T, Dunham-Snary KJ, Oliva CR, et al. The methyl donor S-adenosylmethionine prevents liver hypoxia and dysregulation of mitochondrial bioenergetic function in a rat model of alcohol-induced fatty liver disease. Redox Biol. 2016;9:188-197. DOI: https://doi.org/10.1016/j.redox.2016.08.005
Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock. 2008;30(2):197-205. DOI: https://doi.org/10.1097/SHK.0b013e318160f417
Daswani R, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Role of liver transplantation in severe alcoholic hepatitis. Clin Mol Hepatol. 2018;24(1):43-50. DOI: https://doi.org/10.3350/cmh.2017.0027
Lucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol. 2014;11(5):300-7. DOI: https://doi.org/10.1038/nrgastro.2013.247
Swain MG, Jones DEJ. Fatigue in chronic liver disease: New insights and therapeutic approaches. Liver Int. 2019;39(1):6-19. DOI: https://doi.org/10.1111/liv.13919
Downloads
Published
How to Cite
Issue
Section
